Neurocrine Biosciences Inc (NBIX) stock
Close on Nov 12, 2026Market cap $17.22BP/E 25.1Yield –
Neurocrine Biosciences Inc grew revenue 38.0% to $3.70B over the twelve months to Sep 30, 2026. Operating income rose 61.2% to $887.10M, moving the operating margin from 20.5% to 24.0%. Free cash flow was $1.04B, up 75.3% from a year earlier. At the latest close the market valued the company at $17.22B, 25.1 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $17.22B
- P/E ratio
- 25.1
- Price to sales
- 4.65
- Price to book
- 4.44
- Dividend yield
- –
- Free cash flow yield
- 6.04%
Fundamentals
- Revenue
- $3.70B
- Net income
- $702.50M
- EPS, diluted
- $6.74
- Free cash flow
- $1.04B
- Book value per share
- $36.87
- Diluted shares
- 105M
Trading
- Next earnings
- Feb 10, 2027 (estimated, after the close)
- Previous close
- $174.41
- Open
- $173.98
- Day's range
- $169.22 – $173.98
- Volume
- 1,345,859
- Average volume (20 days)
- 1,432,285
- Index membership
- S&P MidCap 400 (since May 2021), Russell 1000, Russell 3000
- Beta (5 years)
- 0.46
- 52-week range
- $122.14 – $186.12
- RSI (14 days)
- 67.5
- Volatility (1 year)
- 35.2%
- Relative volume
- 1.02×
- WACC
- 7.4%
On 2 of our idea lists: Quality compounders, Quality on sale
Index membership is inferred from the holdings of funds that track each index (IJH, SPMD, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | NBIX | S&P 500 | Difference | NBIX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +19.8% | -2.7% | +22.5 pts | ||
| 3 months | +8.2% | -1.7% | +10.0 pts | ||
| Year to date | +19.4% | +11.9% | +7.5 pts | ||
| 1 year | +15.4% | +12.0% | +3.4 pts | ||
| 3 years | +58.1% | +78.2% | −20.1 pts | +16.5% | +21.2% |
| 5 years | +92.5% | +73.2% | +19.3 pts | +14.0% | +11.6% |
| 10 years | +222.2% | +309.6% | −87.5 pts | +12.4% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Neurocrine Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Results
About Neurocrine Biosciences
Biological Products, (No Diagnostic Substances)
Neurocrine Biosciences is a biopharmaceutical company that discovers, develops, and commercializes therapies for neurological, psychiatric, endocrine, and immunological conditions. Its commercial portfolio features INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, alongside CRENESSITY for classic congenital adrenal hyperplasia. The company also collaborates on therapies for endometriosis and uterine fibroids. In the United States, Neurocrine Biosciences sells its treatments through specialized distribution networks, serving customers that include specialty pharmacy providers, wholesale distributors, and specialty distributors.
Company profile, executives and historyNeurocrine Biosciences stock: common questions
What is Neurocrine Biosciences's stock price?
NBIX closed at $169.40 on Nov 12, 2026, down 2.87% on the day. Over the past 52 weeks it traded between $122.14 and $186.12.
What is Neurocrine Biosciences's market cap?
Neurocrine Biosciences was worth $17.22B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is NBIX's P/E ratio?
NBIX trades at 25.1 times earnings, based on diluted earnings per share of $6.74 over the twelve months to Sep 30, 2026.
How much revenue does Neurocrine Biosciences make?
Neurocrine Biosciences reported revenue of $3.70B for the twelve months to Sep 30, 2026, up 38.0% from a year earlier.
Does Neurocrine Biosciences pay a dividend?
No. Neurocrine Biosciences has not paid a cash dividend over the last twelve months.
When does Neurocrine Biosciences report earnings next?
Neurocrine Biosciences is expected to report Q4 FY2026 results on Feb 10, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has NBIX stock performed over the past year?
Including dividends, NBIX returned +15.4% over the past year, against +12.0% for the S&P 500.
How many NBIX shares are sold short?
6M shares were sold short at the latest FINRA report, 5.88% of the float, or 5.4 days of average trading volume.
Who are Neurocrine Biosciences's competitors?
Companies most similar to Neurocrine Biosciences by business, industry and size include BIIB, BCRX, EXEL, BMRN, JAZZ.
See a number that looks wrong?